Vis enkel innførsel

dc.contributor.authorSæther, Sverre Georg
dc.contributor.authorSchou, Morten Brix
dc.contributor.authorKondziella, Daniel
dc.date.accessioned2017-08-29T08:08:21Z
dc.date.available2017-08-29T08:08:21Z
dc.date.created2017-08-17T10:22:16Z
dc.date.issued2017
dc.identifier.issn1471-244X
dc.identifier.urihttp://hdl.handle.net/11250/2452155
dc.description.abstractBackground:Patients with intracellular onconeural antibodies may present with neuro-psychiatric syndromes. Weaimed to evaluate the evidence for an association between well-characterized onconeural antibodies and psychiatricsymptoms in patients with and without paraneoplastic central nervous system syndromes.Methods:Eligible studies were selected from 1980 until February 2017 according to standardized review criteria andevaluated using Quality Assessment of Diagnostic Accuracy Studies−2 (QUADAS-2). We included studies describing thepsychiatric symptomatology of onconeural antibody positive patients and the prevalence of onconeural antibodies inpatients with psychiatric disorders.Results:Twenty-seven studies met the inclusion criteria. Six studies reported on the prevalence of well-characterizedonconeural antibodies in patients with different psychiatric disorders, ranging from 0% to 4.9%. Antibody prevalence incontrols was available from three studies, ranging from 0% to 2.8%. Data heterogeneity precluded a meta-analysis. Twocerebrospinal fluid studies found well-characterized onconeural antibodies in 3.5% and 0% of patients with psychoticand depressive syndromes, respectively.Conclusions:Theavailableevidencesuggeststhattheprevalenceofwell-characterized onconeural antibodies in patientswith psychiatric disorders is generally low. However, the question whether onconeural antibodies are important in selectpatients with a purely psychiatric phenotype needs to be addressed by appropriately designed studies in the future.nb_NO
dc.language.isoengnb_NO
dc.publisherBioMed Centralnb_NO
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.no*
dc.titleWhat is the significance of onconeural antibodies for psychiatric symptomatology? A systematic reviewnb_NO
dc.typeJournal articlenb_NO
dc.typePeer reviewednb_NO
dc.description.versionpublishedVersionnb_NO
dc.source.volume17nb_NO
dc.source.journalBMC Psychiatrynb_NO
dc.source.issue1nb_NO
dc.identifier.doi10.1186/s12888-017-1325-z
dc.identifier.cristin1486831
dc.description.localcodeThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.nb_NO
cristin.unitcode194,68,30,20
cristin.unitcode194,65,30,0
cristin.unitnameInstitutt for helsevitenskap
cristin.unitnameInstitutt for nevromedisin
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse 4.0 Internasjonal